A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.
Non-Hodgkin's Lymphoma
DRUG: rituximab [MabThera/Rituxan]
Overall objective complete response rate, Day 50|Overall objective partial response rate, Day 50
Progression-free survival, 7 years|Overall survival, 7 years|Duration of response, 7 years|Safety: Incidence of adverse events, 7 years|Level of biological marker bcl2 in peripheral blood and bone marrow, 7 years
This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.